Your browser doesn't support javascript.
Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.
Aschenbrenner, Diane S.
  • Aschenbrenner DS; Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: daschenbrenner@ndm.edu.
Am J Nurs ; 121(2): 26, 2021 Feb 01.
Article in English | MEDLINE | ID: covidwho-1048443
ABSTRACT
A combination of two monoclonal antibodies, casirivimab and imdevimab, has received emergency use authorization for the treatment of mild to moderate COVID-19.Casirivimab and imdevimab come in separate packages but must be combined into one IV infusion after dilution.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Am J Nurs Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Am J Nurs Year: 2021 Document Type: Article